Clinical trial · Interventional
Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer
Sildenafil Prior to Robotic Partial Nephrectomy to Improve Postoperative Renal Function: A Randomized, Placebo-Controlled Pilot Study
NCT01950923CI-TRIAL-00033606completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized pilot clinical trial studies sildenafil citrate before surgery in improving kidney function in patients with kidney cancer. Sildenafil citrate may help protect the kidney from the side effects of surgery and improve kidney function after surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Tumor | Kidney Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| placebo | Other | — | UNRESOLVED |
| sildenafil citrate | Drug | — | UNRESOLVED |
| therapeutic conventional surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm I (sildenafil citrate)
- description
- Patients receive sildenafil citrate PO before the initiation of standard robotic partial nephrectomy.
- interventionNames
- Drug: sildenafil citrate
- Procedure: therapeutic conventional surgery
- type
- PLACEBO_COMPARATOR
- label
- Arm II (placebo)
- description
- Patients receive placebo PO before the initiation of standard robotic partial nephrectomy.
- interventionNames
- Other: placebo
- Procedure: therapeutic conventional surgery
Primary outcomes (3)
- measure
- Accrual rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who are scheduled to undergo robotic partial nephrectomy for suspected renal malignancy * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients with a history of coronary artery disease (including history of myocardial infarction or cardiac stents) or a history of inducible ischemic changes on any prior cardiac stress testing * History of adverse reactions to any phosphodiesterase (PDE) inhibitor (PDE type 5 inhibitor \[PDE5i\]) * Any patient currently taking a PDE5i will be asked to refrain from use for one week prior to their surgery; patients who have used a PDE5i within 72 hours of surgery will be excluded * Pregnant women are excluded from this study * Patients with only one kidney
References
Publications (0)
Data not yet available
No reference posted for this study.